Paxlovid tied to 45% lower risk of poor outcomes in vaccinated outpatientsNonhospitalized, high-risk, vaccinated COVID-19 patients who received nirmatrelvir-ritonavir (NMV-r, or Paxlovid) saw a 45% drop in their relative risk of emergency department (ED) visits, hospitalization, and death by 30 days, suggests a study published late last week in Clinical Infectious Diseases.A team led by Beth Israel Lahey Health researchers in Massachusetts retrospectively analyzed the outcomes of 2,260 nonhospitalized, high-risk adults who had been vaccinated against COVID-19 but had breakthrough infections at least 1 month later from Dec 1, 2021, to Apr 18, 2022.
Half the patients had received Paxlovid within 5 days of diagnosis, and half received standard care.A total of 89 patients (7.9%) who received Paxlovid had an all-cause ED visit, were hospitalized, or died within 30 days, compared with 163 controls (14.4%; odds ratio [OR], 0.5), translating to a 45% relative risk reduction.
No deaths were reported among Paxlovid recipients, compared with 10 in controls.The Paxlovid group also experienced fewer multisystem symptoms and complications such as lower respiratory tract infection, abnormal heart rhythms, and the need for radiologic testing."Our data strongly support the clinical effectiveness of NMV-r in vaccinated patients and the current NIH [National Institutes of Health] guidelines, listing this as the preferred therapy for mild-moderate Covid-19 in those at high risk of severe disease," the researchers wrote.The authors noted that when rebound infections, which have been reported after 5 days of Paxlovid treatment, did occur, they still didn't negate its benefits. "Indeed, we found no late increase in complications among those